TXG 10x Genomics, Inc.
Company Analysis
Latest News
🔴 10x Genomics is trading 4.18% down today as inflation and rate concerns pressure growth stocks
10x Genomics is trading 4.18% down at $77.33 as renewed inflation and interest-rate concerns weigh on U.S. equities. - The Nasdaq Composite is down 1.05%,...
🟢 10x Genomics rises 4.1% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
🟢 10x Genomics is trading 4.3% up today amid technology and AI-linked stock gains
10x Genomics is trading at $79.90, up +4.31%, alongside a stronger risk-on session led by technology and AI-linked stocks. - The S&P 500 is up 0.80% and the...
🟢 10x Genomics rises 5.8% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 10x Genomics is trading 6.1% up today
10x Genomics is trading 6.1% higher at $74.36, with no clear company-specific catalyst identified for September 15, 2026. - Recent coverage highlights an...
🔴 10x Genomics is trading 4.4% down today amid broad technology and risk-asset selling
10x Genomics is trading 4.4% down at $65.57 as broad technology and risk-asset selling pressured the market on September 14, 2026. - The Nasdaq Composite is...
🟢 10x Genomics is trading 5% up today after announcing Lunit AI-pathology collaboration
10x Genomics is trading 4.73% up at $69.52 after announcing a collaboration with Lunit to combine AI-powered pathology analysis with spatial molecular data for...
10x Genomics Target Triples to $68, Following Strong Q2 Earnings Beat
UBS increased its price target for 10x Genomics, Inc. to $68. The new valuation represents a significant rise from the previous $20 target. The firm...
🟢 10x Genomics is trading 5% up today after T. Rowe Price disclosed an 11.7% stake
10x Genomics is trading at $65.84, up +5.09% after T. Rowe Price Associates disclosed an 11.7% stake. - The ownership disclosure was confirmed through an SEC...
10x Genomics Attracts T. Rowe Price Stake, Following 350% Stock Surge
T. Rowe Price Associates, Inc. acquired an 11.7% stake in 10x Genomics, Inc. The institutional investor now beneficially owns 14,044,020 Class A common...
🟢 10x Genomics is trading 4.47% up today after RBC initiated coverage with a Sector Perform rating
10x Genomics is trading 4.47% up at $62.66 after Royal Bank of Canada initiated coverage of its shares with a Sector Perform rating, equivalent to Hold. RBC...
10x Genomics Upgraded to 'Hold' by Royal Bank of Canada
Royal Bank of Canada upgraded 10x Genomics to "Hold." The broader analyst consensus for 10x Genomics remains "Hold." Analysts set an average price target of...
🔴 10x Genomics is trading 4% down today amid a broad biotech sell-off
10x Genomics is trading 4.02% down at $59.94 after biotech shares weakened sharply on September 1, 2026. - XBI biotech ETF is down 4.24%; Nasdaq Composite and...
🔴 10x Genomics falls 4.2% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Casdin Capital Slashes 10x Genomics (TXG) Position by More Than Half
In a quarterly disclosure filed on August 14, 2026, life-sciences investor Casdin Capital revealed a significant reduction in its stake in 10x Genomics (TXG)....
🟢 10x Genomics rises 4.0% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
10x Genomics Loses Sequencing Patent Ruling, Threatening Market Standing
10x Genomics lost a significant patent dispute regarding its sequencing technology. The ruling impacts the company's intellectual property rights and genomics...
🟢 10x Genomics is trading 10.44% up today on positive melanoma-vaccine results
10x Genomics is trading 10.44% up at $61.44 as biotechnology shares rally following positive Phase 3 melanoma-vaccine results from Moderna and Merck. - The...
🟢 10x Genomics is trading 9.49% up today on positive melanoma vaccine results
10x Genomics is trading 9.49% up now at $60.07 as biotechnology shares rally on positive late-stage melanoma vaccine results from Moderna and Merck. - The...
🔴 10x Genomics is trading 4.34% down today as rising yields and oil pressure growth stocks
10x Genomics is trading 4.34% down at $55.47 as growth stocks retreat alongside a weaker Nasdaq and S&P 500. - Rising Treasury yields and higher oil prices...